SIETES :: 93213 citas

Resultados de la búsqueda por QALY REFINAR BÚSQUEDA

1.

Davis S, Martyn-St James M, Sanderson J, Stevens J, Goka E, Rawdin A, Sadler S, Wong R, Campbell F, Stevenson M, Strong M, Selby P, Gittoes N. A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures. Health Technol Assess 2016;20:1-406. [Ref.ID 101044]

2.

McCarthy M. Newer drugs for refractory and relapsed multiple myeloma are effective but costly, review finds. BMJ 2016;353:i2725. [Ref.ID 100423]

3.

Ghinea N, Lipworth W, Kerridge I. Propaganda or the cost of innovation? Challenging the high price of new drugs. BMJ 2016;352:i1284. [Ref.ID 100333]

4.

Hawkes N. Speeding up access to new drugs threatens evidence based medicine, says health economist. BMJ 2016;352:i263. [Ref.ID 99981]

5.

van Eijsden P. Fate of new cancer drug is uncertain in Netherlands, as institute deems it too costly. BMJ 2015;351:h6778. [Ref.ID 99765]

6.

Kmietowicz Z. NICE rejects trastuzumab emtansine for use on NHS. BMJ 2015;351:h6837. [Ref.ID 99764]

7.

Maynard A, Bloor K. Regulation of the pharmaceutical industry: promoting health or protecting wealth?. J R Soc Med 2015;108:220-2. [Ref.ID 99099]

8.

Najafzadeh M, Andersson K, Shrank WH, Krumme AA, Matlin OS, Brennan T, Avorn J, Choudhry NK. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med 2015;162:407-19. [Ref.ID 98960]

9.

Chinthapalli K. NICE is dead; long live NICE. BMJ 2013;346:16. [Ref.ID 95480]

10.

Anónimo. An introduction to the method of cost-effectiveness analysis. Drug Ther Bull 2012;50:81-4. [Ref.ID 93356]

11.

Raftery J, Chorozoglou M. Possible net harms of breast cancer screening: updated modelling of Forrest report. BMJ 2012;344:14. [Ref.ID 92216]

12.

13.

Gage BF. Cost of dabigatran for atrial fibrillation. BMJ 2011;343:915-6. [Ref.ID 91803]

14.

Noyes K, Bajorska A, Chappel A, Schwid SR, Mehta LR, Weinstock-Guttman B, Holloway RG, Dick AW. Cost-effectiveness of disease-modifying therapy for multiple sclerosis. A population-based study. Neurology 2011;77:355-63. [Ref.ID 90812]

15.

Nayak S, Roberts MS, Greenspan SL. Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women. Ann Intern Med 2011;155:751-61. [Ref.ID 90509]

16.

Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, Wang PJ, Turakhia MP. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med 2011;154:1-11. [Ref.ID 90077]

17.

John-Baptiste A, Bell C. Industry sponsored bias in cost effectiveness analyses. BMJ 2011;342:4-5. [Ref.ID 89996]

18.

Anónimo. A guide to health economic evaluations. Drug Ther Bull 2010;48:105-8. [Ref.ID 89279]

19.

Duerden M. From a cancer drug fund to value based pricing of drugs. BMJ 2010;341:412-3. [Ref.ID 89253]

20.

Wise J. NICE approved 80% of drugs it evaluated in past decade. BMJ 2010;341:168. [Ref.ID 88927]